Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Director | March 19, 2026 | March 23, 2026 |
| MEDICINES CO /DEMDCO · Entity 152552 | Director | May 25, 2018 | May 29, 2018 |
| SYNERGY PHARMACEUTICALS, INC.SGYP · Entity 164269 | Director | August 15, 2018 | August 16, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2032-02-17 | Direct | 16,941 |
Reported balance
After 2026-03-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-19 · Grant · Acquired 16,941 · Balance 16,941 F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.31 · Expires 2032-02-17 | Direct | 0 |
Reported balance
After 2026-03-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-19 · Disposition to issuer · Disposed 16,941 · Balance 0 F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2032-05-11 | Direct | 10,362 |
Reported balance
After 2026-03-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-19 · Grant · Acquired 10,362 · Balance 10,362 F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.28 · Expires 2032-05-11 | Direct | 0 |
Reported balance
After 2026-03-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-19 · Disposition to issuer · Disposed 10,362 · Balance 0 F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2033-06-06 | Direct | 23,742 |
Reported balance
After 2026-03-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-19 · Grant · Acquired 23,742 · Balance 23,742 F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.91 · Expires 2033-06-06 | Direct | 0 |
Reported balance
After 2026-03-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-19 · Disposition to issuer · Disposed 23,742 · Balance 0 F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
F2: The option is fully vested.
F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
MEDICINES CO /DE
Report date May 25, 2018 · Filed May 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,133 |
Ending reported balance
After 2018-05-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-05-25 · Exercise / conversion · Acquired 7,500 · Balance 60,633 Row 2 · 2018-05-25 · Sale · Disposed 7,500 · Balance 53,133 |
| Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.30 · Expires 2018-05-29 | Direct | 0 |
Reported balance
After 2018-05-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-25 · Exercise / conversion · Disposed 7,500 · Balance 0 F1: This option vested in twelve equal monthly installments beginning June 29, 2008. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vested in twelve equal monthly installments beginning June 29, 2008.
SYNERGY PHARMACEUTICALS, INC.
Report date August 15, 2018 · Filed August 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,305 |
Ending reported balance
After 2018-08-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-08-15 · Exercise / conversion · Acquired 150,000 · Balance 150,000 Row 2 · 2018-08-15 · Tax withholding · Disposed 101,695 · Balance 48,305 F1: Represents the number of shares forfeited to the Company in payment of the exercise price of the stock options. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2018-08-21 | Direct | 474,364 |
Reported balance
After 2018-08-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-15 · Exercise / conversion · Disposed 150,000 · Balance 474,364 F2: Options became exercisable on 8/21/2009, 2010 and 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares forfeited to the Company in payment of the exercise price of the stock options.
F2: Options became exercisable on 8/21/2009, 2010 and 2011.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2026 Filed Mar 23, 2026 23:04 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 23,742 | Not disclosed Strike: $5.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120207 · ownership.xml · derivative · entry 6 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:04 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 23,742 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120207 · ownership.xml · derivative · entry 5 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:04 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 10,362 | Not disclosed Strike: $17.28 | Not disclosed |
DisclosureSEC source: 0001193125-26-120207 · ownership.xml · derivative · entry 4 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,362 shares Expires 2032-05-11 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:04 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 10,362 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120207 · ownership.xml · derivative · entry 3 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,362 Underlying: Common Stock · 10,362 shares Expires 2032-05-11 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:04 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 16,941 | Not disclosed Strike: $9.31 | Not disclosed |
DisclosureSEC source: 0001193125-26-120207 · ownership.xml · derivative · entry 2 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,941 shares Expires 2032-02-17 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:04 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 16,941 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120207 · ownership.xml · derivative · entry 1 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,941 Underlying: Common Stock · 16,941 shares Expires 2032-02-17 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:21 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 20,400 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001193125-26-064061 · ownership.xml · derivative · entry 1 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2036-02-19 F1 · derivative.exercise_date: The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:57 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 19,111 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0000950170-25-077058 · ownership.xml · derivative · entry 1 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,111 Underlying: Common Stock · 19,111 shares Expires 2035-05-21 F1 · derivative.exercise_date: The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 21:58 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 64,503 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076374 · ownership.xml · derivative · entry 1 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,503 Underlying: Common Stock · 64,503 shares Expires 2034-06-18 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date. Read SEC document |
| June 07, 2023 Filed Jun 10, 2023 00:37 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 23,742 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0000899243-23-015310 · doc4.xml · derivative · entry 1 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:18 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 10,362 | $0.00 Strike: $17.28 | $0.00 |
DisclosureSEC source: 0000899243-22-018281 · doc4.xml · derivative · entry 1 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,362 Underlying: Common Stock · 10,362 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/12 of the shares shall vest on each monthly anniversary as measured from March 25, 2022. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 17:00 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | Exercise / conversionStock Options · Derivative | 150,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001104659-18-052475 · a4.xml · derivative · entry 3 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,364 Underlying: Common Stock · 150,000 shares Expires 2018-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options became exercisable on 8/21/2009, 2010 and 2011. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 17:00 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | Tax withholdingCommon Stock | 101,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-052475 · a4.xml · nonDerivative · entry 2 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,305 F1 · shares: Represents the number of shares forfeited to the Company in payment of the exercise price of the stock options. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 17:00 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | Exercise / conversionCommon Stock | 150,000 | $1.20 | $180,000.00 |
DisclosureSEC source: 0001104659-18-052475 · a4.xml · nonDerivative · entry 1 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2018 Filed Jun 19, 2018 16:32 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | GrantStock Options · Derivative | 114,750 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001104659-18-041066 · a4.xml · derivative · entry 1 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624,364 Underlying: Common Stock · 114,750 shares Expires 2028-06-16 F1 · shares: Represents the annual grant of stock options to each outside independent board member of the issuer. Read SEC document |
| May 25, 2018 Filed May 29, 2018 17:03 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionStock Option (right-to-buy) · Derivative | 7,500 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001179110-18-007621 · edgar.xml · derivative · entry 3 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2018-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vested in twelve equal monthly installments beginning June 29, 2008. Read SEC document |
| May 25, 2018 Filed May 29, 2018 17:03 UTC | MEDICINES CO /DE MDCO · Entity 152552 | SaleCommon Stock | 7,500 | $32.20 | $241,500.00 |
DisclosureSEC source: 0001179110-18-007621 · edgar.xml · nonDerivative · entry 2 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,133 Read SEC document |
| May 25, 2018 Filed May 29, 2018 17:03 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionCommon Stock | 7,500 | $18.30 | $137,250.00 |
DisclosureSEC source: 0001179110-18-007621 · edgar.xml · nonDerivative · entry 1 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 17:08 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001104659-17-043012 · a4.xml · derivative · entry 3 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,614 Underlying: Common Stock · 12,000 shares Expires 2019-11-20 F1 · shares: The reported transactions with this same footnote involved an amendment of an outstanding option, resulting in the deemed cancellation of the old option and the grant of a replacement option. The old option was originally granted on November 20, 2009. The vesting schedule of the old option was reported on a Form 3 filed by the reporting person on August 3, 2011. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 17:08 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | Disposition to issuerStock Options · Derivative | 12,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001104659-17-043012 · a4.xml · derivative · entry 2 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 497,614 Underlying: Common Stock · 12,000 shares Expires 2019-11-20 F1 · shares: The reported transactions with this same footnote involved an amendment of an outstanding option, resulting in the deemed cancellation of the old option and the grant of a replacement option. The old option was originally granted on November 20, 2009. The vesting schedule of the old option was reported on a Form 3 filed by the reporting person on August 3, 2011. F1 · derivative.exercise_date: The reported transactions with this same footnote involved an amendment of an outstanding option, resulting in the deemed cancellation of the old option and the grant of a replacement option. The old option was originally granted on November 20, 2009. The vesting schedule of the old option was reported on a Form 3 filed by the reporting person on August 3, 2011. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 17:08 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | GrantStock Options · Derivative | 62,500 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001104659-17-043012 · a4.xml · derivative · entry 1 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,614 Underlying: Common Stock · 62,500 shares Expires 2027-06-28 Read SEC document |
| May 25, 2017 Filed May 30, 2017 19:40 UTC | MEDICINES CO /DE MDCO · Entity 152552 | GrantStock Option (right-to-buy · Derivative | 8,577 | $0.00 Strike: $39.39 | $0.00 |
DisclosureSEC source: 0001179110-17-008214 · edgar.xml · derivative · entry 2 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,577 Underlying: Common Stock · 8,577 shares Expires 2027-05-25 F2 · derivative.exercise_date: This option vests in one installment on May 25, 2018 and is made as part of and pursuant to Issuer's director compensation package. Read SEC document |
| May 25, 2017 Filed May 30, 2017 19:40 UTC | MEDICINES CO /DE MDCO · Entity 152552 | GrantCommon Stock | 3,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-008214 · edgar.xml · nonDerivative · entry 1 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,133 F1 · shares: This restricted stock award vests on May 25, 2018 and is made as part of and pursuant to Issuer's director compensation package. Read SEC document |
| May 23, 2017 Filed May 25, 2017 17:08 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionStock Option (right-to-buy) · Derivative | 7,500 | Not disclosed Strike: $19.60 | Not disclosed |
DisclosureSEC source: 0001179110-17-008011 · edgar.xml · derivative · entry 2 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2017-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: This option vested in twelve equal monthly installments beginning on June 24, 2007. Read SEC document |
| May 23, 2017 Filed May 25, 2017 17:08 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionCommon Stock | 7,500 | $19.60 | $147,000.00 |
DisclosureSEC source: 0001179110-17-008011 · edgar.xml · nonDerivative · entry 1 Spigelman Melvin K · CIK 0001339901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.